<DOC>
	<DOCNO>NCT01560546</DOCNO>
	<brief_summary>A randomized , placebo-controlled , double-blinded study 40 men type 2 DM . Type 2 diabetes mellitus ( T2DM ) common endocrine disorder characterize hyperinsulinaemia insulin resistance . Hypothesis Testosterone therapy increase lean body mass insulin sensitivity men low normal level bioavailable testosterone type 2 DM .</brief_summary>
	<brief_title>Testosterone Therapy Men With Type 2 Diabetes Mellitus ( T2DM )</brief_title>
	<detailed_description>Background Inadequate level androgens associate increase risk chronic illness include obesity diabetes . Moreover , testosterone treatment show increase lean body mass lipid oxidation well insulin sensitivity hypogonadal men .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Male gender age 5070 Bioavailable testosterone &lt; 7,3 nmol/L Metformin treatment T2DM 3 month HbA1c &gt; 9,0 % , BMI &gt; 40 kg/m2 , Haematocrit &gt; 50 % , Known malignant disease , PSA &gt; 3 ug/L , Nycturia &gt; 3 time , Abnormal routine blood sample , Severe hypertension , Significant EKGchanges , Wish parenthood , Active mental illness , former present abuse , Severe illness heart , lung kidney , Primary secondary hypogonadism .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>